Effects of the pharmaceutical technologic aspects of oral pediatric drugs on patient-related outcomes: A systematic literature review

Clinical Therapeutics

Volumn 32, Issue 5, 2010, Pages 924-938

  van Riet Nales, Diana A ^a,b   Schobben, Alfred F A M ^b   Egberts, Toine C G ^b,c   Rademaker, Carin M A ^c  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Administration; Child; Oral; Pharmaceutical; Pharmaceutical preparations; Technology; Treatment outcome

Indexed keywords

ANTIBIOTIC AGENT; CENTRAL STIMULANT AGENT; DRUG;

DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG PACKAGING; DRUG TOLERABILITY; HUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACEUTICAL ENGINEERING; REVIEW; SYSTEMATIC REVIEW; TASTE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; OFF-LABEL USE; PATIENT PREFERENCE; PEDIATRICS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 77954793874     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.05.005     Document Type: Review

References (122)

1. Balakrishnan K, Grieve J, Tordoff J, et al. Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002. J Clin Pharmacol. 2006, 46:1038-1043.
2. Young L, Lawes F, Tordoff J, et al. Access to prescribing information for paediatric medicines in the USA: Postmodernization. Br J Clin Pharmacol. 2009, 67:341-346.
3. Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children [published correction appears in: Arch Pediatr Adolesc Med. 2007;161:655]. Arch Pediatr Adolesc Med. 2007, 161:282-290.
4. Kumar P, Walker JK, Hurt KM, et al. Medication use in the neonatal intensive care unit: Current patterns and off-label use of parenteralmedications. J Pediatr. 2008, 152:412-415.
5. One Hundred Fifth Congress of the United States of America. Food and Drug Administration Modernization Act of 1997 (S.830) Accessed October 1, 2009. http://www.fda.gov/downloads/Medical/Devices/DeviceRegulationandGuidance/Overview/MedicalDeviceProvisionsofFDAModernizationAct/UCM136669.pdf.
6. One Hundred Eighth Congress of the United States of America. Pediatric Research Equity Act of 2003 (S.650) Accessed October 1, 2009. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077853.pdf.
7. One Hundred Seventh Congress of the United States of America. Best Pharmaceuticals for Children Act (S.1789) Accessed October 1, 2009. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049874.pdf.
8. One Hundred Tenth Congress of the United States of America. FDA Amendments Act of 2007 (H.R.6432) Accessed October 1, 2009. http://www.fda.gov/downloads/ForIndustry/UserFees/AnimalGenericDrugUserFeeActAGDUFA/UCM164309.pdf.
9. Grieve J, Tordoff J, Reith D, Norris P Effect of the pediatric exclusivity provision on children's access to medicines. Br J Clin Pharmacol. 2005, 59:730-735.
10. Milne CP, Bruss JB The economics of pediatric formulation development for off-patent drugs. Clin Ther. 2008, 30:2133-2145.
11. Balakrishnan K, Tordoff J, Norris P, Reith D Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002. Br J Clin Pharmacol. 2007, 63:85-91.
12. Chui J, Tordoff J, Kennedy J, Reith D Trends in accessibility to medicines for children in New Zealand: 1998-2002. Br J Clin Pharmacol. 2004, 57:322-327.
13. Chui J, Tordoff J, Reith D Changes in availability of paediatric medicines in Australia between 1998 and 2002. Br J Clin Pharmacol. 2005, 59:736-742.
14. Cuzzolin L, Zaccaron A, Fanos V Unlicensed and off-label uses of drugs in paediatrics: A review of the literature. Fundam Clin Pharmacol. 2003, 17:125-131.
15. Horen B, Montastruc JL, Lapeyre-Mestre M Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002, 54:665-670.
16. Hsien L, Breddemann A, Frobel AK, et al. Off-label drug use among hospitalised children: Identifying areas with the highest need for research. Pharm World Sci. 2008, 30:497-502.
17. Jain SS, Bavdekar SB, Gogtay NJ, Sadawarte PA Off-label drug use in children. Indian J Pediatr. 2008, 75:1133-1136.
18. Santos DB, Clavenna A, Bonati M, Coelho HL Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. EurJ Clin Pharmacol. 2008, 64:1111-1118.
19. Winterfeld U, Le Heuzey MF, Acquaviva E, et al. Psychotropic medication use in the child and adolescent psychiatry wards of a French hospital. Pharm World Sci. 2008, 30:600-604.
20. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union 2006, L378/1. European Commission Enterprise and Industry Directorate General Consumer Goods Pharmaceuticals, Accessed April 15, 2010. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf.
21. Auby P Pharmaceutical research in paediatric populations and the new EU Paediatric Legislation: An industry perspective. Child Adolesc Psychiatry Ment Health 2008, 2:38.
22. European Medicines Agency Committee for Medicinal Products for Human Use. Reflection paper: Formulations of choice for the paediatric population Accessed October 1, 2009. http://www.EMA.europa.eu/pdfs/human/paediatrics/19481005en.pdf.
23. European Medicines Agency Committee for Medicinal Products for Human Use, Paediatric Committee, and Committee on Herbal Medicinal Products. Concept paper on the development of a quality guideline on pharmaceutical development of medicines for paediatric use Accessed October 1, 2009. http://www.EMEA.europa.eu/pdfs/human/qwp/13893108enpdf.
24. Matsui D, Lim R, Tschen T, Rieder MJ Assessment of the palatability of beta-lactamase-resistant antibiotics in children. Arch Pediatr Adolesc Med. 1997, 151:599-602.
25. Ameen VZ, Pobiner BF, Giguere GC, Carter EG Ranitidine (Zantac) syrup versus Ranitidine effervescent tablets (Zantac) EFFERdose in children: A single-center taste preference study. Paediatr Drugs. 2006, 8:265-270.
26. Hirve S, Bhave S, Bavdekar A, et al. Low dose 'Sprinkles'-An innovative approach to treat iron deficiency anemia in infants and young children. Indian Pediatr. 2007, 44:91-100.
27. Yildirim SV, Guc BU, Bozdogan N, Tokel K Oral versus intranasal midazolam premedication for infants during echocardiographic study. AdvTher. 2006, 23:719-724.
28. Zlotkin S, Arthur P, Antwi KY, Yeung G Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia. Pediatrics. 2001, 108:613-616.
29. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials. 1996, 17.
30. WHO Collaborating Centre for Drug Statistics Methodology. ATC/ DDD Index 2010. vailable at: Assessed December 15, 2009. http://www.whocc.no/atc_ddd_index/.
31. Martinez JM, Bartoli F, Recaldini E, et al. A taste comparison of two different liquid colecalciferol (vitamin D3) preparations in healthy new-borns and infants. Clin Drug Investig. 2006, 26:663-665.
32. Marcus SC, Wan GJ, Kemner JE, Olfson M Continuity of methyl-phenidate treatment for attention-deficit/hyperactivity disorder [published correction appears in Arch Pediatr Adolesc Med. 2005;159:875]. Arch Pediatr Adolesc Med. 2005, 159:572-578.
33. Tolia V, Johnston G, Stolle J, Lee C Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup: In children aged between 5-11 years. Paediatr Drugs. 2004, 6.
34. Aydintug YS, Okcu KM, Guner Y, et al. Evaluation of oral or rectal midazolam as conscious sedation for pediatric patients in oral surgery. Mil Med. 2004, 169:270-273.
35. Fine B, Castillo R, McDonald T, et al. Jet injector compared with oral midazolam for preoperative sedation in children. Paediatr Anaesth. 2004, 14:739-743.
36. Cheng KK Children's acceptance and tolerance of chlorhexidine and benzydamine oral rinses in the treatment of chemotherapy-induced oropharyngeal mucositis. Eur J Oncol Nurs. 2004, 8:341-349.
37. Cifaldi MA, Paris MM, Devcich KJ, Bukofzer S Parent-reported outcomes for treatment of acute otitis media with cefdinir or amoxicillin/ clavulanate oral suspensions. Paediatr Drugs. 2004, 6:387-393.
38. Dagnone D, Matsui D, Rieder MJ Assessment of the palatability of vehicles for activated charcoal in pediatric volunteers. Pediatr Emerg Care. 2002, 18:19-21.
39. Sundberg AK, Smith LD, Somerville KT, et al. Conversion from cyclosporine to tacrolimus is preferred by pediatric renal transplant recipients: A focus on opinions and outcomes. Transplant Proc. 2002, 34:1951-1952.
40. Patchell CJ, Desai M, Weller PH, et al. Creon 10,000 Minimicrospheres vs. Creon 8,000 microspheres-an open randomised crossover preference study. J Cyst Fibros. 2002, 1:287-291.
41. Guenther Skokan E, Junkins EP, Corneli HM, Schunk JE Taste test: Children rate flavoring agents used with activated charcoal. Arch Pediatr Adolesc Med. 2001, 155:683-686.
42. Yeboah-Antwi K, Gyapong JO, Asare IK, et al. Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment. Bull World Health Organ. 2001, 79:394-399.
43. Ansah EK, Gyapong JO, Agyepong IA, Evans DB Improving adherence to malaria treatment for children: The use of pre-packed chloroquine tablets vs. chloroquine syrup. Trop Med Int Health 2001, 6:496-504.
44. Okonkwo PO, Akpala CO, Okafor HU, et al. Compliance to correct dose of chloroquine in uncomplicated malaria correlates with improvement in the condition of rural Nigerian children. Trans R Soc Trop Med Hyg. 2001, 95:320-324.
45. Zlotkin S, Arthur P, Antwi KY, Yeung G Treatment of anemia with micro-encapsulated ferrous fumarate plus ascorbic acid supplied as sprinkles to complementary (weaning) foods. Am J Clin Nutr. 2001, 74:791-795.
46. Scharman EJ, Cloonan HA, Durback-Morris LF Home administration of charcoal: Can mothers administer a therapeutic dose?. J Emerg Med. 2001, 21:357-361.
47. Damrikarnlert L, Jauregui AC, Kzadri M Efficacy and safety of amoxycillin/clavulanate (Augmentin) twice daily versus three times daily in the treatment of acute otitis media in children. J Chemother 2000, 12:79-87. Augmentin 454 Study Group.
48. Te Water Naude JM, Donald PR, Hussey GD, et al. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatr Infect Dis J. 2000, 19:405-410.
49. Powers JL, Gooch WM, Oddo LP Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr Infect Dis J. 2000, 19(Suppl 12):S174-S180.
50. McCrindle BW, O'Neill MB, Cullen-Dean G, Helden E Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: A randomized, crossover trial. J Pediatr. 1997, 130:266-273.
51. Prince AP, McMurray MP, Buist NR Treatment products and approaches for phenylketonuria: Improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials. J Inherit Metab Dis. 1997, 20:486-498.
52. Tonstad S, Sivertsen M, Aksnes L, Ose L Low dose colestipol in adolescents with familial hypercholesterolaemia. Arch Dis Child. 1996, 74:157-160.
53. El-Chaar GM, Mardy G, Wehlou K, Rubin LG Randomized, double blind comparison of brand and generic antibiotic suspensions: II. A study of taste and compliance in children. Pediatr Infect Dis J. 1996, 15:18-22.
54. Stevens R, Votan B, Lane R, et al. A randomized study of ondansetron syrup in children: Evaluation of taste acceptability and tolerance. Pediatr Hematol Oncol. 1996, 13:199-202.
55. Matsui D, Barron A, Rieder MJ Assessment of the palatability of antistaphylococcal infection in pediatric volunteers. Ann Pharmacother. 1996, 30:586-588.
56. Powers JL Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Pediatr Infect Dis J. 1996, 15(Suppl 9):S30-S37.
57. Ellerbeck E, Khallaf N, Ansary KS, et al. Caretaker compliance with different antibiotic formulations for treatment of childhood pneumonia. J Trop Pediatr. 1995, 41:103-108.
58. Dagan R, Shvartzman P, Liss Z Variation in acceptance of common oral antibiotic suspensions. Pediatr Infect Dis J. 1994, 13:686-690.
59. Karl HW, Rosenberger JL, Larach MG, Ruffle JM Transmucosal administration of midazolam for premedication of pediatric patients. Comparison of the nasal and sublingual routes. Anesthesiology 1993, 78:885-891.
60. Cloyd JC, Kriel RL, Jones-Saete CM, et al. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J Pediatr. 1992, 120:634-638.
61. Bagger-Sjöbäck D, Bondesson G Taste evaluation and compliance of two paediatric formulations of phenoxymethylpenicillin in children. Scand J Prim Health Care 1989, 7:87-92.
62. Saarnivaara L, Lindgren L, Klemola UM Comparison of chloral hydrate and midazolam by mouth as premedicants in children undergoing otolaryngological surgery. Br J Anaesth. 1988, 61:390-396.
63. Francis JR, Addy M, Hunter B A comparison of three delivery methods of chlorhexidine in handicapped children. II. Parent and house-parent preferences. J Periodontol. 1987, 58:456-459.
64. Kenna MA, Bluestone CD, Fall P, et al. Cefixime vs. cefaclor in the treatment of acute otitis media in infants and children. Pediatr Infect Dis J. 1987, 6:992-996.
65. Jahnsen T, Thorn P An acceptability study of two pivampicillin mixtures in children in general practice. Scand J Prim Health Care 1987, 5:241-243.
66. Uhari M, Eskelinen L, Jokisalo J Acceptance of antibiotic mixtures by infants and children. Eur J Clin Pharmacol. 1986, 30:503-504.
67. Jaffé G, Grimshaw JJ Randomized single-blind trial in general practice comparing the efficacy and palatability of two cough linctus preparations, 'Pholcolix' and 'sActifed' Compound, in children with acute cough. Curr Med Res Opin. 1983, 8:594-599.
68. Pugliese WM, Mesches DN, Wiersum J, et al. Double-blind study: Cleocin Palmitate and Erythrocin Pediatric in otitis media in children. Curr Ther Res Clin Exp. 1972, 14:31-34.
69. Block SL, Schmier JK, Notario GF, et al. Efficacy, tolerability, and parent reported outcomes for cefdinir vs. high-dose amoxicillin/clavulanate oral suspension for acute otitis media in young children. Curr Med Res Opin. 2006, 22:1839-1847.
70. LePrevost M, Green H, Flynn J, et al. Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J. 2006, 25:533-537. Pediatric European Network for the Treatment of AIDS 13 Study Group.
71. Tolia V, Han C, North JD, Amer F Taste comparisons for lansoprazole strawberry-flavoured delayed-release orally disintegrating tablet and ranitidine peppermint-flavoured syrup in children. Clin Drug Investig. 2005, 25:285-292.
72. Awasthi S, Verma T, Vir S Effectiveness of biweekly versus daily ironfolic acid administration on anaemia status in preschool children. J Trop Pediatr. 2005, 51:67-71.
73. Angelilli ML, Toscani M, Matsui DM, Rieder MJ Palatability of oral infection among children in an urban primary care center. Arch Pediatr Adolesc Med. 2000, 154:267-270.
74. Gooch WM, Adelglass J, Kelsey DK, et al. Loracarbefversus clarithromycin in children with acute otitis media with effusion. Clin Ther. 1999, 21:711-722.
75. Behre U, Burow HM, Quinn P, et al. Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children. Infection. 1997, 25:163-166.
76. Cook RC, Zachariah J, Cree F, Harrison HE Efficacy of twice-daily amoxycillin/clavulanate ('Augmentin-Duo' 400/57) in mild to moderate lower respiratory tract infection in children. Br J Clin Pract. 1996, 50:125-128.
77. Doran O, Austin NC, Taylor BJ Vitamin K administration in neonates: Survey of compliance with recommended practices in the Dunedin area. N Z Med J. 1995, 108:337-339.
78. Tarpay M, Marks MI, Hopkins C, San Joaquin VH Cefaclor therapy twice daily for acute otitis media. Controlled comparative study of twicedaily vs thrice-daily dose schedule. Am J Dis Child. 1982, 136:33-35.
79. Rosaschino F, Cattaneo L Strategies for optimizing compliance of paediatric patients for seasonal antibacterial vaccination with sublingually administered Polyvalent Mechanical Bacterial Lysates (PMBL). Acta Biomed. 2004, 75:171-178.
80. Toscani M, Drehobl M, Freed J, Stool S A multicenter, randomized, comparative assessment in healthy pediatric volunteers of the palatability of oral infection effective in the therapy of otitis media. Curr Ther Res Clin Exp. 2000, 61:278-285.
81. Schwartz RH Enhancing children's satisfaction with antibiotic therapy: A taste study of several antibiotic suspensions. Curr Ther Res Clin Exp. 2000, 61:570-581.
82. Holmberg L A comparative taste preference study of loratadine versus terfenadine in children. Curr Ther Res Clin Exp. 1994, 55:641-644.
83. Sunderland R, McVey DL, Atkin KJ Cefixime versus co-amoxiclav in the treatment of pediatric upper respiratory tract infections and otitis media. A multicenter clinical study of empirical treatment in general practice in the United Kingdom. Curr Ther Res Clin Exp. 1994, 55(Suppl A):22-29.
84. Frush KS, Luo X, Hutchinson P, Higgins JN Evaluation of a method to reduce over-the-counter medication dosing error. Arch Pediatr Adolesc Med. 2004, 158:620-624.
85. Kogan A, Katz J, Efrat R, Eidelman LA Premedication with midazolam in young children: A comparison of four routes of administration. Paediatr Anaesth 2002, 12:685-689.
86. Geldner G, Hubmann M, Knoll R, Jacobi K Comparison between three transmucosal routes of administration of midazolam in children. Paediatr Anaesth 1997, 7:103-109.
87. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extendedrelease methylphenidate formulations in children with attentiondeficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004, 113:e206-e216. COMACS Study Group.
88. Pelham WE, Gnagy EM, Chronis AM, et al. A comparison of morningonly and morning/late afternoon Adderall to morning-only, twicedaily, and three times-daily methylphenidate in children with attentiondeficit/hyperactivity disorder. Pediatrics 1999, 104:1300-1311.
89. Manos MJ, Short EJ, Findling RL Differential effectiveness of methyl-phenidate and Adderall in schoolage youths with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999, 38:813-819.
90. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attentiondeficit/hyperactivity disorder. Pediatrics 2001, 108:883-892.
91. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001, 107:E105.
92. Gribetz B, Cronley SA Underdosing of acetaminophen by parents. Pediatrics 1987, 80:630-633.
93. Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J. 1997, 16:463-470.
94. Ellison RS, Altemeier WA Effect of use of a measured dispensing device on oral antibiotic compliance. Clin Pediatr (Phila) 1982, 21:668-671.
95. Pichichero M, Aronovitz GH, Gooch WM, et al. Comparison of cefuroxime axetil, cefaclor, and amoxicillin-clavulanate potassium suspensions in acute otitis media in infants and children. South Med J. 1990, 83:1174-1177.
96. Eeg-Olofsson O, Nilsson HL, Tonnby B, et al. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: A comparison between conventional and slow-release formulations. J Child Neurol 1990, 5:159-165.
97. Block SL, McCarty JM, Hedrick JA, et al. Comparative safety and efficacy of cefdinir vs amoxicillin/clavulanate for treatment of suppurative acute otitis media in children. Pediatr Infect Dis J. 2000, 19(Suppl 12):S159-S165. Cefdinir Otitis Media Study Group.
98. Block SL, Cifaldi M, Gu Y, Paris MM A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: A multicenter, prospective, single-blind study. Clin Ther. 2005, 27:786-794.
99. Malinovsky JM, Populaire C, Cozian A, et al. Premedication with midazolam in children. Effect of intranasal, rectal and oral routes on plasma midazolam concentrations. Anaesthesia 1995, 50:351-354.
100. Almenrader N, Passariello M, Coccetti B, et al. Premedication in children: A comparison of oral midazolam and oral clonidine. Paediatr Anaesth 2007, 17:1143-1149.
101. Gordon CM, Williams AL, Feld-man HA, et al. Treatment of hypovitaminosis D in infants and toddlers. J Clin Endocrin Metab 2008, 93:2716-2721.
102. Herranz JL, Arteaga R, Adín J, Armijo JA Conventional and sustained-release valproate in children with newly diagnosed epilepsy: A randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics. Eur J Clin Pharmacol 2006, 62:805-815.
103. Isik B, Baygin O, Bodur H Effect of drinks that are added as flavoring in oral midazolam premedication on sedation success [published correction appears in Pediatr Anaesth. 2008;18:1016]. Paediatr Anaesth 2008, 18:494-500.
104. Meier CM, Simonetti GD, Ghiglia S, et al. Palatability of angiotensin II antagonists among nephropathic children. Br J Clin Pharmacol 2007, 63:628-631. CHIld Project.
105. Sabri M, Di Lorenzo C, Henderson W, et al. Colon cleansing with oral sodium phosphate in adolescents: Dose, efficacy, acceptability, and safety. Am J Gastroenterol 2008, 103:1533-1539. quiz 1540.
106. Penali LK, Jansen FH Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plasmodium falciparum malaria. Int J Infect Dis. 2008, 12:430-437.
107. Schachar R, Ickowicz A, Crosbie J, et al. Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008, 18:11-24.
108. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: Results of an 11-year randomized study. Clin Infect Dis. 2007, 45:715-722.
109. Lottmann H, Froeling F, Alloussi S, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract. 2007, 61:1454-1460.
110. Brosius KK, Bannister CF Midazolam premedication in children: A comparison of two oral dosage formulations on sedation score and plasma midazolam levels. Anesth Analg 2003, 96:392-395. table of contents.
111. Brouwer OF, Pieters MS, Edelbroek PM, et al. Conventional and controlled release valproate in children with epilepsy: A crossover study comparing plasma levels and cognitive performances. Epilepsy Res. 1992, 13:245-253.
112. Khalil SN, Vije HN, Kee SS, et al. A paediatric trial comparing midazolam/Syrpalta mixture with premixed midazolam syrup (Roche). Paediatr Anaesth 2003, 13:205-209.
113. Pelham WE, Sturges J, Hoza J, et al. Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 1987, 80:491-501.
114. Weiss M, Hechtman L, Turgay A, et al. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyper-activity disorder. J Child Adolesc Psychopharmacol 2007, 17:675-688.
115. Döpfner M, Gerber WD, Banaschewski T, et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):I93-I101.
116. Geltman PL, Hironaka LK, Mehta SD, et al. Iron supplementation of low-income infants: A randomized clinical trial of adherence with ferrous fumarate sprinkles versus ferrous sulfate drops. J Pediatr 2009, 154:738-743.
117. Kumar A, Srivastava U, Saxena S, et al. Midazolam for preanaesthetic medication in children: Nasal vs oral administration. J Anaesth Clin Pharmacol 2007, 18:387-391.
118. le Roux SM, Cotton MF, Golub JE, et al. Adherence to isoniazid prophylaxis among HIV-infected children: A randomized controlled trial comparing two dosing schedules. BMC Med. 2009, 7:67.
119. Purswani MU, Radhakrishnan J, Irfan KR, et al. Infant acceptance of a bitter-tasting liquid medication: A randomized controlled trial comparing the Rx Medibottle with an oral syringe. Arch Pediatr Adolesc Med. 2009, 163:186-188.
120. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Q8(R2) guideline on pharmaceutical development US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Accessed March 1, 2010, Accessed March 1, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073507.pdf.
121. Thomson SA, Tuleu C, Wong IC, et al. Minitablets: New modality to deliver medicines to preschoolaged children. Pediatrics 2009, 123:e235-e258.
122. Urquhart J, Vrijens B New findings about patient adherence to prescribed drug dosing regimens: An introduction to pharmionics. EurJ Hosp Ph Sc. 2005, 11:103-106.